Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belantamab mafodotin - GSK

Next Previous
X
Search
Drug Profile

Belantamab mafodotin - GSK

Alternative Names: anti-BCMA-ADC - GSK ; Belamaf; belantamab mafodotin-blmf; blenrep; BLENREP; GSK'916; GSK-2857916; J6M0-mcMMAF

Latest Information Update: 12 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Amgen; Atrium Health; GSK
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Plasmablastic lymphoma

Most Recent Events

  • 07 Jun 2024 Efficacy and adverse events data from a phase III DREAMM-7 trial in multiple melanoma released by GlaxoSmithKline
  • 03 Jun 2024 Efficacy and adverse events data from a phase III DREAMM 8 trial in Multiple myeloma released by GSK
  • 31 May 2024 Updated efficacy and adverse event data from the phase III DREAMM-7 trial in Mutiple myeloma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top